Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Backer Marianne De Sells 72,995 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CEO Backer Marianne De sold 72,995 shares of the stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $9.46, for a total transaction of $690,532.70. Following the transaction, the chief executive officer now owns 678,457 shares of the company's stock, valued at approximately $6,418,203.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Vir Biotechnology Trading Down 2.3 %

Shares of NASDAQ:VIR traded down $0.22 on Thursday, reaching $9.47. 909,108 shares of the company's stock were exchanged, compared to its average volume of 1,091,114. Vir Biotechnology, Inc. has a twelve month low of $7.72 and a twelve month high of $27.48. The company has a fifty day moving average of $10.20 and a 200-day moving average of $9.65. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -2.06 and a beta of 0.41.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its earnings results on Thursday, February 22nd. The company reported ($0.86) earnings per share for the quarter, beating analysts' consensus estimates of ($1.14) by $0.28. The firm had revenue of $16.80 million during the quarter, compared to the consensus estimate of $11.18 million. Vir Biotechnology had a negative return on equity of 34.92% and a negative net margin of 713.69%. The company's revenue was down 66.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.76) EPS. As a group, equities research analysts forecast that Vir Biotechnology, Inc. will post -4.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Vir Biotechnology

Several hedge funds have recently added to or reduced their stakes in the business. Hudson Bay Capital Management LP increased its position in shares of Vir Biotechnology by 1,975.0% during the 3rd quarter. Hudson Bay Capital Management LP now owns 207,500 shares of the company's stock valued at $1,944,000 after purchasing an additional 197,500 shares during the last quarter. Barclays PLC boosted its stake in shares of Vir Biotechnology by 124.6% during the 3rd quarter. Barclays PLC now owns 412,161 shares of the company's stock worth $3,863,000 after acquiring an additional 228,634 shares during the last quarter. State of Alaska Department of Revenue raised its holdings in Vir Biotechnology by 205.5% in the 3rd quarter. State of Alaska Department of Revenue now owns 153,494 shares of the company's stock worth $1,438,000 after purchasing an additional 103,246 shares during the period. Schonfeld Strategic Advisors LLC lifted its position in Vir Biotechnology by 582.9% during the third quarter. Schonfeld Strategic Advisors LLC now owns 162,128 shares of the company's stock valued at $1,519,000 after purchasing an additional 138,387 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in Vir Biotechnology in the third quarter worth about $1,098,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

VIR has been the subject of several analyst reports. HC Wainwright reissued a "buy" rating and issued a $110.00 target price on shares of Vir Biotechnology in a research note on Friday, March 15th. JPMorgan Chase & Co. upped their target price on shares of Vir Biotechnology from $9.00 to $10.00 and gave the company a "neutral" rating in a report on Friday, February 23rd. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Vir Biotechnology has a consensus rating of "Moderate Buy" and an average target price of $34.38.

About Vir Biotechnology

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.